Anika Therapeutics Inc.

The grade, in three tenses

Headline 5.5 out of ten, 9 of 9 metrics filed: past 5.6 out of ten, present 5.3 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

• Surviving crises (past): 6.3 out of ten. 2 warning events since 2017; the latest 2017-05-05. 63rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Track record (past): 3.5 out of ten. +1% a year over 10 filed years; profitable in 5 of 10. 35th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Shareholder treatment (past): 8.7 out of ten. Share count shrank 1.0% a year. 100% of cash flow returned. Insiders: 0 sales, 4 purchases. 87th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Financial health (present): 7.3 out of ten. ROE -8%: lost 8¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar. 73rd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Industry position (present): 4.6 out of ten. bottom 46% of 109 in its family; net margin -9.6%. 46th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Leadership (present): 2.5 out of ten. bottom 25% of 90 in its family for leadership; chief executive since 2026. 25th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
• Room to expand (future): 6.1 out of ten. top 39% of 104 in its family for room to expand. 61st percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Growth drivers (future): 4.4 out of ten. bottom 44% of 105 in its family for growth drivers. 44th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Expectations vs reality (future): 6.4 out of ten. top 36% of 88 in its family for expectations against reality. 64th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-03 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-29 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-29 (on EDGAR). Newest filing: Form 144, 2026-08-07. Filings on record since 1996. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: OEM Channel 57%, Commercial Channel 43%. By geography: United States 62%, Europe 20%, Other Location 18%. As tagged in its annual report (Form 10-K, filed 2026-03-03).

Who runs it

Griffin, Stephen D. (President and CEO); Blanchard, Cheryl R (President, CEO, Director); Mcleod, Ian (SVP, CAO & Treasurer); Colleran, David (EVP, General Counsel, Corp Sec); Fischetti, Gary P (director); Capper, Joseph H (director); Conley, Sheryl L (director); Henneman, John B III (director); Richard, Stephen (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.